Publications (Lab members are in bold)
42. Zinc Carnosine Metal-Organic Coordination Polymer as a Potent Broadly Active Influenza Vaccine Platform with In Vitro Shelf-Stability.
Hendy DA, Lifshits LM, Batty CJ, Carlock MA, Ross TM, Mousa JJ, Bachelder EM, Ainslie KM. Mol Pharm. 2023 Sep 4;20(9):4687-4697. doi: 10.1021/acs.molpharmaceut.3c00424. Epub 2023 Aug 21.PMID: 37603310
41. Structural basis of the amidase ClbL central to the biosynthesis of the genotoxin colibactin.
Tripathi P, Mousa JJ, Guntaka NS, Bruner SD. Acta Crystallogr D Struct Biol. 2023 Sep 1;79(Pt 9):830-836. doi: 10.1107/S2059798323005703. Epub 2023 Aug 10.PMID: 37561403
40. Structural basis for respiratory syncytial virus and human metapneumovirus neutralization.
Miller RJ, Mousa JJ. Curr Opin Virol. 2023 Aug;61:101337. doi: 10.1016/j.coviro.2023.101337.PMID: 37544710.
39. Epitope Binning of Monoclonal and Polyclonal Antibodies by Biolayer Interferometry.
Nagashima K, Mousa JJ. Methods Mol Biol. 2023;2673:17-32. doi: 10.1007/978-1-0716-3239-0_2. PMID: 37258904
38. A general computational design strategy for stabilizing viral class I fusion proteins.
Gonzalez KJ, Huang J, Criado MF, Banerjee A, Tompkins S, Mousa JJ, Strauch EM. bioRxiv. 2023 Mar 17:2023.03.16.532924. doi: 10.1101/2023.03.16.532924. Preprint. PMID: 36993551
37. Structural insights into the broad protection against H1 influenza viruses by a computationally optimized hemagglutinin vaccine.
Dzimianski JV, Han J, Sautto GA, O'Rourke SM, Cruz JM, Pierce SR, Ecker JW, Carlock MA, Nagashima KA, Mousa JJ, Ross TM, Ward AB, DuBois RM. Commun Biol. 2023 Apr 25;6(1):454. doi: 10.1038/s42003-023-04793-3. PMID: 37185989
36. Human Metapneumovirus (hMPV) Infection and MPV467 Treatment in Immunocompromised Cotton Rats Sigmodon hispidus.
Yim KC, Mousa JJ, Blanco JCG, Kim S, Boukhvalova MS. Viruses. 2023 Feb 9;15(2):476. doi: 10.3390/v15020476. PMID: 36851691
35. Adjuvant-Mediated Differences in Antibody Responses to Computationally Optimized Hemagglutinin and Neuraminidase Vaccines.
Nagashima K, Abbadi N, Vyas V, Roegner A, Ross TM, Mousa JJ. Viruses. 2023 Jan 25;15(2):347. doi: 10.3390/v15020347. PMID: 36851561
34. Immunogenicity and protective efficacy of a pan-fungal vaccine in preclinical models of aspergillosis, candidiasis, and pneumocystosis.
Rayens E, Rabacal W, Willems HME, Kirton GM, Barber JP, Mousa JJ, Celia-Sanchez BN, Momany M, Norris KA. PNAS Nexus. 2022 Nov 4;1(5):pgac248. doi: 10.1093/pnasnexus/pgac248. eCollection 2022 Nov. PMID: 36712332
33. Broadly Protective Neuraminidase-Based Influenza Vaccines and Monoclonal Antibodies: Target Epitopes and Mechanisms of Action.
Abbadi N, Mousa JJ. Viruses. 2023 Jan 10;15(1):200. doi: 10.3390/v15010200. PMID: 36680239
32. Structural characterization of protective non-neutralizing antibodies targeting Crimean-Congo hemorrhagic fever virus.
Durie IA, Tehrani ZR, Karaaslan E, Sorvillo TE, McGuire J, Golden JW, Welch SR, Kainulainen MH, Harmon JR, Mousa JJ, Gonzalez D, Enos S, Koksal I, Yilmaz G, Karakoc HN, Hamidi S, Albay C, Spengler JR, Spiropoulou CF, Garrison AR, Sajadi MM, Bergeron É, Pegan SD. Nat Commun. 2022 Nov 26;13(1):7298. doi: 10.1038/s41467-022-34923-0. PMID: 36435827
31. Antibodies as drugs-a Keystone Symposia report.
Cable J, Saphire EO, Hayday AC, Wiltshire TD, Mousa JJ, Humphreys DP, Breij ECW, Bruhns P, Broketa M, Furuya G, Hauser BM, Mahévas M, Carfi A, Cantaert T, Kwong PD, Tripathi P, Davis JH, Brewis N, Keyt BA, Fennemann FL, Dussupt V, Sivasubramanian A, Kim PM, Rawi R, Richardson E, Leventhal D, Wolters RM, Geuijen CAW, Sleeman MA, Pengo N, Donnellan FR. Ann N Y Acad Sci. 2023 Jan;1519(1):153-166. doi: 10.1111/nyas.14915. Epub 2022 Nov 16. PMID: 36382536
30. Synergistic Protection against Secondary Pneumococcal Infection by Human Monoclonal Antibodies Targeting Distinct Epitopes.
Gingerich AD, Royer F, McCormick AL, Scasny A, Vidal JE, Mousa JJ. J Immunol. 2023 Jan 1;210(1):50-60. doi: 10.4049/jimmunol.2200349. Epub 2022 Nov 9. PMID: 36351696
29. A Pan-Pneumovirus vaccine based on immunodominant epitopes of the fusion protein.
Huang J, Miller RJ, Mousa JJ. Front Immunol. 2022 Aug 8;13:941865. PMID: 36003370
28. Pediatric burden and seasonality of human metapneumovirus over 5 years in Managua, Nicaragua.
Hacker K, Kuan G, Vydiswaran N, Chowell-Puente G, Patel M, Sanchez N, Lopez R, Ojeda S, Lopez B, Mousa J, Maier HE, Balmaseda A, Gordon A. Influenza Other Respir Viruses. 2022 Aug 14. doi: 10.1111/irv.13034. PMID: 35965382
27. Differential Recognition of Computationally Optimized H3 Hemagglutinin Influenza Vaccine Candidates by Human Antibodies.
Abbadi N, Nagashima K, Pena-Briseno A, Ross TM, Mousa JJ. J Virol. 2022 Aug 24;96(16):e0089622. Epub 2022 Aug 2. PMID: 35916534
26. Structural basis for ultrapotent neutralization of human metapneumovirus
Avik Banerjee, Jiachen Huang, Scott A. Rush, Jackelyn Murray, Aaron D. Gingerich, Fredejah Royer, Ching-Lin Hsieh, Ralph A. Tripp, Jason S. McLellan, Jarrod J. Mousa. bioRxiv 2022.03.14.484292; doi: https://doi.org/10.1101/2022.03.14.484292
25. The Pre-Existing Human Antibody Repertoire to Computationally Optimized Influenza H1 Hemagglutinin Vaccines.
Nagashima K, Dzimianski JV, Han J, Abbadi N, Gingerich AD, Royer F, O'Rourke S, Sautto GA, Ross TM, Ward AB, DuBois RM, Mousa JJ. J Immunol. 2022 Jul 1;209(1):5-15. PMID: 35697384.
24. Diverse Mechanisms of Protective Anti-Pneumococcal Antibodies.
Gingerich, A.D., Mousa, J.J. Front. Cell Infect. Microbiol. 2022. https://doi.org/10.3389/fcimb.2022.824788
23. Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine.
An D, Li K, Rowe DK, Diaz MCH, Griffin EF, Beavis AC, Johnson SK, Padykula I, Jones CA, Briggs K, Li G, Lin Y, Huang J, Mousa J, Brindley M, Sakamoto K, Meyerholz DK, McCray PB Jr, Tompkins SM, He B. Sci Adv. 2021 Jul 2;7(27):eabi5246. PMID: 34215591
22. Structure, immunogenicity, and conformation-dependent receptor binding of the post-fusion human metapneumovirus F protein.
Huang J, Chopra P, Liu L, Nagy T, Murray J, Tripp RA, Boons GJ, Mousa JJ. J Virol. 2021 95(18):e0059321. PMID: 34160259
21. A Structural Model for the Ligand Binding of Pneumococcal Serotype 3 Capsular Polysaccharide-Specific Protective Antibodies.
Ozdilek A, Huang J, Babb R, Paschall AV, Middleton DR, Duke JA, Pirofski LA, Mousa JJ, Avci FY. mBio. 2021 12(3):e0080021. PMID: 34061603
20. Next-Generation Influenza HA Immunogens and Adjuvants in Pursuit of a Broadly Protective Vaccine.
Nagashima KA, Mousa JJ. Viruses. 2021 13(4):546. PMID: 33805245
19. Pneumocystis Pneumonia: Immunity, Vaccines, and Treatments.
Gingerich AD, Norris KA, Mousa JJ. Pathogens. 2021 10(2):236. PMID: 33669726
18. Broadly reactive human monoclonal antibodies targeting the pneumococcal histidine triad protein protect against fatal pneumococcal infection.
Huang J, Gingerich AD, Royer F, Paschall AV, Pena-Briseno A, Avci FY, Mousa JJ. Infect Immun. 2021 Mar 1:IAI.00747-20. PMID: 33649050
17. Potent Henipavirus Neutralization by Antibodies Recognizing Diverse Sites on Hendra and Nipah Virus Receptor Binding Protein.
Dong J, Cross RW, Doyle MP, Kose N, Mousa JJ, Annand EJ, Borisevich V, Agans KN, Sutton R, Nargi R, Majedi M, Fenton KA, Reichard W, Bombardi RG, Geisbert TW, Crowe JE Jr. Cell. 2020 183(6):1536-1550.e17. PMID: 33306954
16. Antibody recognition of the Pneumovirus fusion protein trimer interface.
Huang J, Diaz D, Mousa JJ. PLoS Pathog. 2020 16(10):e1008942. PMID: 33035266
15. Characterization of the β-glucuronidase Pn3Pase as the founding member of glycoside hydrolase family GH169.
Wantuch PL, Jella S, Duke JA, Mousa JJ, Henrissat B, Glushka J, Avci FY. Glycobiology. 2020 doi: 10.1093/glycob/cwaa070. PMID: 32810871
14. Isolation and characterization of new human carrier peptides from two important vaccine immunogens.
Wantuch PL, Sun L, LoPilato RK, Mousa JJ, Haltiwanger RS, Avci FY. Vaccine. 2020 38(10):2315-2325. PMID: 32005537
13. Antibody Epitopes of Pneumovirus Fusion Proteins.
Huang J, Diaz D, Mousa JJ. Front Immunol. 2019 10:2778. PMID: 31849961
12. Structural and antigenic characterization of a computationally-optimized H5 hemagglutinin influenza vaccine.
Bar-Peled Y, Huang J, Nuñez IA, Pierce SR, Ecker JW, Ross TM, Mousa JJ. Vaccine. 37(41):6022-6029. PMID: 31481254
11. A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human Metapneumovirus In Vivo.
Bar-Peled Y, Diaz D, Pena-Briseno A, Murray J, Huang J, Tripp RA, Mousa JJ.J Virol. 2019 12;93(19):e00342-19. PMID: 31292250
10. Human antibody recognition of antigenic site IV on Pneumovirus fusion proteins.
Mousa JJ, Binshtein E, Human S, Fong RH, Alvarado G, Doranz BJ, Moore ML, Ohi MD, Crowe JE Jr. PLoS Pathog. 2018 14(2):e1006837. PMID: 29470533
9. A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein.
Mousa JJ, Kose N, Matta P, Gilchuk P, Crowe JE Jr.Nat Microbiol. 2017 2:16271. PMID: 28134924
8. Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus.
Wen X, Mousa JJ, Bates JT, Lamb RA, Crowe JE Jr, Jardetzky TS. Nat Microbiol. 2017 2:16272. PMID: 28134915
7. The PacC transcription factor regulates secondary metabolite production and stress response, but has only minor effects on virulence in the insect pathogenic fungus Beauveria bassiana.
Luo Z, Ren H, Mousa JJ, Rangel DE, Zhang Y, Bruner SD, Keyhani NO. Environ Microbiol. 2017 19(2):788-802. PMID: 28083986
6. ClbM is a versatile, cation-promiscuous MATE transporter found in the colibactin biosynthetic gene cluster.
Mousa JJ, Newsome RC, Yang Y, Jobin C, Bruner SD. Biochem Biophys Res Commun. 2017 482(4):1233-1239. PMID: 27939886
5. Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.
Mousa JJ, Sauer MF, Sevy AM, Finn JA, Bates JT, Alvarado G, King HG, Loerinc LB, Fong RH, Doranz BJ, Correia BE, Kalyuzhniy O, Wen X, Jardetzky TS, Schief WR, Ohi MD, Meiler J, Crowe JE Jr. Proc Natl Acad Sci U S A. 2016 113(44):E6849-E6858. PMID: 27791117
4. Structural and mechanistic diversity of multidrug transporters.
Mousa JJ, Bruner SD.Nat Prod Rep. 2016 33(11):1255-1267.
3. MATE transport of the E. coli-derived genotoxin colibactin.
Mousa JJ, Yang Y, Tomkovich S, Shima A, Newsome RC, Tripathi P, Oswald E, Bruner SD, Jobin C. Nat Microbiol. 2016 1:15009. PMID: 27571755
2. A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV.
Wen X, Pickens J, Mousa JJ, Leser GP, Lamb RA, Crowe JE Jr, Jardetzky TS. PLoS One. 2016 11(5):e0155917. PMID: 27224013
1. Bbmsn2 acts as a pH-dependent negative regulator of secondary metabolite production in the entomopathogenic fungus Beauveria bassiana.
Luo Z, Li Y, Mousa J, Bruner S, Zhang Y, Pei Y, Keyhani NO. Environ Microbiol. 2015 17(4):1189-202. PMID: 24965521
Hendy DA, Lifshits LM, Batty CJ, Carlock MA, Ross TM, Mousa JJ, Bachelder EM, Ainslie KM. Mol Pharm. 2023 Sep 4;20(9):4687-4697. doi: 10.1021/acs.molpharmaceut.3c00424. Epub 2023 Aug 21.PMID: 37603310
41. Structural basis of the amidase ClbL central to the biosynthesis of the genotoxin colibactin.
Tripathi P, Mousa JJ, Guntaka NS, Bruner SD. Acta Crystallogr D Struct Biol. 2023 Sep 1;79(Pt 9):830-836. doi: 10.1107/S2059798323005703. Epub 2023 Aug 10.PMID: 37561403
40. Structural basis for respiratory syncytial virus and human metapneumovirus neutralization.
Miller RJ, Mousa JJ. Curr Opin Virol. 2023 Aug;61:101337. doi: 10.1016/j.coviro.2023.101337.PMID: 37544710.
39. Epitope Binning of Monoclonal and Polyclonal Antibodies by Biolayer Interferometry.
Nagashima K, Mousa JJ. Methods Mol Biol. 2023;2673:17-32. doi: 10.1007/978-1-0716-3239-0_2. PMID: 37258904
38. A general computational design strategy for stabilizing viral class I fusion proteins.
Gonzalez KJ, Huang J, Criado MF, Banerjee A, Tompkins S, Mousa JJ, Strauch EM. bioRxiv. 2023 Mar 17:2023.03.16.532924. doi: 10.1101/2023.03.16.532924. Preprint. PMID: 36993551
37. Structural insights into the broad protection against H1 influenza viruses by a computationally optimized hemagglutinin vaccine.
Dzimianski JV, Han J, Sautto GA, O'Rourke SM, Cruz JM, Pierce SR, Ecker JW, Carlock MA, Nagashima KA, Mousa JJ, Ross TM, Ward AB, DuBois RM. Commun Biol. 2023 Apr 25;6(1):454. doi: 10.1038/s42003-023-04793-3. PMID: 37185989
36. Human Metapneumovirus (hMPV) Infection and MPV467 Treatment in Immunocompromised Cotton Rats Sigmodon hispidus.
Yim KC, Mousa JJ, Blanco JCG, Kim S, Boukhvalova MS. Viruses. 2023 Feb 9;15(2):476. doi: 10.3390/v15020476. PMID: 36851691
35. Adjuvant-Mediated Differences in Antibody Responses to Computationally Optimized Hemagglutinin and Neuraminidase Vaccines.
Nagashima K, Abbadi N, Vyas V, Roegner A, Ross TM, Mousa JJ. Viruses. 2023 Jan 25;15(2):347. doi: 10.3390/v15020347. PMID: 36851561
34. Immunogenicity and protective efficacy of a pan-fungal vaccine in preclinical models of aspergillosis, candidiasis, and pneumocystosis.
Rayens E, Rabacal W, Willems HME, Kirton GM, Barber JP, Mousa JJ, Celia-Sanchez BN, Momany M, Norris KA. PNAS Nexus. 2022 Nov 4;1(5):pgac248. doi: 10.1093/pnasnexus/pgac248. eCollection 2022 Nov. PMID: 36712332
33. Broadly Protective Neuraminidase-Based Influenza Vaccines and Monoclonal Antibodies: Target Epitopes and Mechanisms of Action.
Abbadi N, Mousa JJ. Viruses. 2023 Jan 10;15(1):200. doi: 10.3390/v15010200. PMID: 36680239
32. Structural characterization of protective non-neutralizing antibodies targeting Crimean-Congo hemorrhagic fever virus.
Durie IA, Tehrani ZR, Karaaslan E, Sorvillo TE, McGuire J, Golden JW, Welch SR, Kainulainen MH, Harmon JR, Mousa JJ, Gonzalez D, Enos S, Koksal I, Yilmaz G, Karakoc HN, Hamidi S, Albay C, Spengler JR, Spiropoulou CF, Garrison AR, Sajadi MM, Bergeron É, Pegan SD. Nat Commun. 2022 Nov 26;13(1):7298. doi: 10.1038/s41467-022-34923-0. PMID: 36435827
31. Antibodies as drugs-a Keystone Symposia report.
Cable J, Saphire EO, Hayday AC, Wiltshire TD, Mousa JJ, Humphreys DP, Breij ECW, Bruhns P, Broketa M, Furuya G, Hauser BM, Mahévas M, Carfi A, Cantaert T, Kwong PD, Tripathi P, Davis JH, Brewis N, Keyt BA, Fennemann FL, Dussupt V, Sivasubramanian A, Kim PM, Rawi R, Richardson E, Leventhal D, Wolters RM, Geuijen CAW, Sleeman MA, Pengo N, Donnellan FR. Ann N Y Acad Sci. 2023 Jan;1519(1):153-166. doi: 10.1111/nyas.14915. Epub 2022 Nov 16. PMID: 36382536
30. Synergistic Protection against Secondary Pneumococcal Infection by Human Monoclonal Antibodies Targeting Distinct Epitopes.
Gingerich AD, Royer F, McCormick AL, Scasny A, Vidal JE, Mousa JJ. J Immunol. 2023 Jan 1;210(1):50-60. doi: 10.4049/jimmunol.2200349. Epub 2022 Nov 9. PMID: 36351696
29. A Pan-Pneumovirus vaccine based on immunodominant epitopes of the fusion protein.
Huang J, Miller RJ, Mousa JJ. Front Immunol. 2022 Aug 8;13:941865. PMID: 36003370
28. Pediatric burden and seasonality of human metapneumovirus over 5 years in Managua, Nicaragua.
Hacker K, Kuan G, Vydiswaran N, Chowell-Puente G, Patel M, Sanchez N, Lopez R, Ojeda S, Lopez B, Mousa J, Maier HE, Balmaseda A, Gordon A. Influenza Other Respir Viruses. 2022 Aug 14. doi: 10.1111/irv.13034. PMID: 35965382
27. Differential Recognition of Computationally Optimized H3 Hemagglutinin Influenza Vaccine Candidates by Human Antibodies.
Abbadi N, Nagashima K, Pena-Briseno A, Ross TM, Mousa JJ. J Virol. 2022 Aug 24;96(16):e0089622. Epub 2022 Aug 2. PMID: 35916534
26. Structural basis for ultrapotent neutralization of human metapneumovirus
Avik Banerjee, Jiachen Huang, Scott A. Rush, Jackelyn Murray, Aaron D. Gingerich, Fredejah Royer, Ching-Lin Hsieh, Ralph A. Tripp, Jason S. McLellan, Jarrod J. Mousa. bioRxiv 2022.03.14.484292; doi: https://doi.org/10.1101/2022.03.14.484292
25. The Pre-Existing Human Antibody Repertoire to Computationally Optimized Influenza H1 Hemagglutinin Vaccines.
Nagashima K, Dzimianski JV, Han J, Abbadi N, Gingerich AD, Royer F, O'Rourke S, Sautto GA, Ross TM, Ward AB, DuBois RM, Mousa JJ. J Immunol. 2022 Jul 1;209(1):5-15. PMID: 35697384.
24. Diverse Mechanisms of Protective Anti-Pneumococcal Antibodies.
Gingerich, A.D., Mousa, J.J. Front. Cell Infect. Microbiol. 2022. https://doi.org/10.3389/fcimb.2022.824788
23. Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine.
An D, Li K, Rowe DK, Diaz MCH, Griffin EF, Beavis AC, Johnson SK, Padykula I, Jones CA, Briggs K, Li G, Lin Y, Huang J, Mousa J, Brindley M, Sakamoto K, Meyerholz DK, McCray PB Jr, Tompkins SM, He B. Sci Adv. 2021 Jul 2;7(27):eabi5246. PMID: 34215591
22. Structure, immunogenicity, and conformation-dependent receptor binding of the post-fusion human metapneumovirus F protein.
Huang J, Chopra P, Liu L, Nagy T, Murray J, Tripp RA, Boons GJ, Mousa JJ. J Virol. 2021 95(18):e0059321. PMID: 34160259
21. A Structural Model for the Ligand Binding of Pneumococcal Serotype 3 Capsular Polysaccharide-Specific Protective Antibodies.
Ozdilek A, Huang J, Babb R, Paschall AV, Middleton DR, Duke JA, Pirofski LA, Mousa JJ, Avci FY. mBio. 2021 12(3):e0080021. PMID: 34061603
20. Next-Generation Influenza HA Immunogens and Adjuvants in Pursuit of a Broadly Protective Vaccine.
Nagashima KA, Mousa JJ. Viruses. 2021 13(4):546. PMID: 33805245
19. Pneumocystis Pneumonia: Immunity, Vaccines, and Treatments.
Gingerich AD, Norris KA, Mousa JJ. Pathogens. 2021 10(2):236. PMID: 33669726
18. Broadly reactive human monoclonal antibodies targeting the pneumococcal histidine triad protein protect against fatal pneumococcal infection.
Huang J, Gingerich AD, Royer F, Paschall AV, Pena-Briseno A, Avci FY, Mousa JJ. Infect Immun. 2021 Mar 1:IAI.00747-20. PMID: 33649050
17. Potent Henipavirus Neutralization by Antibodies Recognizing Diverse Sites on Hendra and Nipah Virus Receptor Binding Protein.
Dong J, Cross RW, Doyle MP, Kose N, Mousa JJ, Annand EJ, Borisevich V, Agans KN, Sutton R, Nargi R, Majedi M, Fenton KA, Reichard W, Bombardi RG, Geisbert TW, Crowe JE Jr. Cell. 2020 183(6):1536-1550.e17. PMID: 33306954
16. Antibody recognition of the Pneumovirus fusion protein trimer interface.
Huang J, Diaz D, Mousa JJ. PLoS Pathog. 2020 16(10):e1008942. PMID: 33035266
15. Characterization of the β-glucuronidase Pn3Pase as the founding member of glycoside hydrolase family GH169.
Wantuch PL, Jella S, Duke JA, Mousa JJ, Henrissat B, Glushka J, Avci FY. Glycobiology. 2020 doi: 10.1093/glycob/cwaa070. PMID: 32810871
14. Isolation and characterization of new human carrier peptides from two important vaccine immunogens.
Wantuch PL, Sun L, LoPilato RK, Mousa JJ, Haltiwanger RS, Avci FY. Vaccine. 2020 38(10):2315-2325. PMID: 32005537
13. Antibody Epitopes of Pneumovirus Fusion Proteins.
Huang J, Diaz D, Mousa JJ. Front Immunol. 2019 10:2778. PMID: 31849961
12. Structural and antigenic characterization of a computationally-optimized H5 hemagglutinin influenza vaccine.
Bar-Peled Y, Huang J, Nuñez IA, Pierce SR, Ecker JW, Ross TM, Mousa JJ. Vaccine. 37(41):6022-6029. PMID: 31481254
11. A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human Metapneumovirus In Vivo.
Bar-Peled Y, Diaz D, Pena-Briseno A, Murray J, Huang J, Tripp RA, Mousa JJ.J Virol. 2019 12;93(19):e00342-19. PMID: 31292250
10. Human antibody recognition of antigenic site IV on Pneumovirus fusion proteins.
Mousa JJ, Binshtein E, Human S, Fong RH, Alvarado G, Doranz BJ, Moore ML, Ohi MD, Crowe JE Jr. PLoS Pathog. 2018 14(2):e1006837. PMID: 29470533
9. A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein.
Mousa JJ, Kose N, Matta P, Gilchuk P, Crowe JE Jr.Nat Microbiol. 2017 2:16271. PMID: 28134924
8. Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus.
Wen X, Mousa JJ, Bates JT, Lamb RA, Crowe JE Jr, Jardetzky TS. Nat Microbiol. 2017 2:16272. PMID: 28134915
7. The PacC transcription factor regulates secondary metabolite production and stress response, but has only minor effects on virulence in the insect pathogenic fungus Beauveria bassiana.
Luo Z, Ren H, Mousa JJ, Rangel DE, Zhang Y, Bruner SD, Keyhani NO. Environ Microbiol. 2017 19(2):788-802. PMID: 28083986
6. ClbM is a versatile, cation-promiscuous MATE transporter found in the colibactin biosynthetic gene cluster.
Mousa JJ, Newsome RC, Yang Y, Jobin C, Bruner SD. Biochem Biophys Res Commun. 2017 482(4):1233-1239. PMID: 27939886
5. Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.
Mousa JJ, Sauer MF, Sevy AM, Finn JA, Bates JT, Alvarado G, King HG, Loerinc LB, Fong RH, Doranz BJ, Correia BE, Kalyuzhniy O, Wen X, Jardetzky TS, Schief WR, Ohi MD, Meiler J, Crowe JE Jr. Proc Natl Acad Sci U S A. 2016 113(44):E6849-E6858. PMID: 27791117
4. Structural and mechanistic diversity of multidrug transporters.
Mousa JJ, Bruner SD.Nat Prod Rep. 2016 33(11):1255-1267.
3. MATE transport of the E. coli-derived genotoxin colibactin.
Mousa JJ, Yang Y, Tomkovich S, Shima A, Newsome RC, Tripathi P, Oswald E, Bruner SD, Jobin C. Nat Microbiol. 2016 1:15009. PMID: 27571755
2. A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV.
Wen X, Pickens J, Mousa JJ, Leser GP, Lamb RA, Crowe JE Jr, Jardetzky TS. PLoS One. 2016 11(5):e0155917. PMID: 27224013
1. Bbmsn2 acts as a pH-dependent negative regulator of secondary metabolite production in the entomopathogenic fungus Beauveria bassiana.
Luo Z, Li Y, Mousa J, Bruner S, Zhang Y, Pei Y, Keyhani NO. Environ Microbiol. 2015 17(4):1189-202. PMID: 24965521